Related Experiment Videos
Dexamethasone inhalations in RSV bronchiolitis: a double-blind, placebo-controlled study
Lea Bentur1, David Shoseyov, David Feigenbaum
1Pediatric Pulmonology Unit, Meyer Children's Hospital, Rambam Medical Center, and the Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. l_bentur@rambam.health.gov.il
Acta Paediatrica (Oslo, Norway : 1992)
|September 29, 2005
Summary
Inhaled dexamethasone may shorten hospital stays for infants with respiratory syncytial virus (RSV) bronchiolitis, particularly for premature infants. This treatment showed a reduced length of hospitalization in a clinical trial.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Respiratory syncytial virus (RSV) bronchiolitis is a common lower respiratory tract infection in infants.
- Hospitalization is often required for severe cases, necessitating effective treatment strategies.
- The role of inhaled corticosteroids in managing RSV bronchiolitis remains an area of investigation.
Purpose of the Study:
- To investigate the efficacy of inhaled dexamethasone in reducing hospitalization duration for infants diagnosed with RSV bronchiolitis.
- To compare the outcomes of inhaled dexamethasone versus placebo in a double-blind, randomized controlled trial.
Main Methods:
- A double-blind, placebo-controlled study involving 61 infants (3-12 months) with bronchiolitis.
- Participants received either nebulized dexamethasone or normal saline, alongside standard epinephrine nebulizations.
- Follow-up assessments were conducted for up to 3 months post-treatment.
Main Results:
- No significant differences were observed in clinical scores, oxygen saturation, or intravenous fluid requirements between the groups.
- Kaplan-Meier analysis revealed a significantly shorter cumulative in-hospital stay in the dexamethasone group (p<0.038).
- A subgroup analysis indicated that prematurely born infants receiving inhaled dexamethasone had a markedly reduced hospitalization period (p<0.018).
Conclusions:
- Inhaled dexamethasone demonstrates potential in decreasing the length of hospitalization for infants suffering from acute viral bronchiolitis.
- The therapeutic benefit appears more pronounced in prematurely born infants.
- Further research may elucidate optimal dosing and long-term effects.